Eloxx Pharmaceuticals Announces Changes to Board of Directors
July 05 2022 - 8:00AM
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal
RNA-targeted genetic therapies for rare diseases, today announced
the appointment of Lindsay Androski, JD, MBA to its board of
directors and as a member of the Board’s Audit Committee and
Compensation Committee. Current board members Gadi Veinrib, Ran
Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir
Seehra have stepped down from the board. Following these changes,
Eloxx’s board is now comprised of five directors.
“Lindsay is a veteran biotech executive with
significant experience growing companies during her long tenure
with the founding team of Roivant Sciences and now as President and
CEO of Roivant Social Ventures,” said Sumit Aggarwal, President and
CEO of Eloxx Pharmaceuticals. “Her current focus on early stage
biotech companies improving health access will be extremely
valuable to Eloxx as we continue to build a leadership position in
genetic therapy.”
“I am passionate about companies like Eloxx that are focused on
addressing unmet needs for underserved patient populations. I am
excited to join the board of Eloxx and to contribute to the
company’s work in developing therapies for rare diseases,” said Ms.
Androski.
“In addition, I would like to express my sincerest gratitude to
Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh
and Dr. Jasbir Seehra, for their dedication, impactful
contributions, and valuable insights as they helped Eloxx navigate
through challenging times,” said Sumit Aggarwal. “This smaller
board, nimble and focused by design, supports the transformation we
started in April 2021 with our acquisition of Zikani.”
Ms. Androski, JD, MBA is founder, President and CEO of Roivant
Social Ventures, a social impact organization that makes early
stage investments and incubates biotech companies focused on
improving healthcare access and outcomes for underserved groups. A
noted expert in the creation, launch and scaling of biotech
companies, Ms. Androski joined the founding team at Roivant
Sciences to build and lead the group responsible for the in-license
or acquisition of more than 30 pharmaceutical drug candidates,
where she was also instrumental in the launch of 16 biotech
companies and participated in three IPOs and several private
financings. To date, these efforts have led to five approved drugs
now available to patients: Orgovyx (prostate cancer), Myfembree
(heavy menstrual bleeding / uterine fibroids), Gemtesa (overactive
bladder), Rethymic (pediatric congenital athymia), and VTAMA
(plaque psoriasis). Prior to joining Roivant Sciences, Ms. Androski
spent a decade as a trial lawyer, including four years as an
Assistant U.S. Attorney in the newly-launched Cybercrime unit of
the Eastern District of Virginia, where she led investigations and
prosecutions of high-profile cybercrime and national security
cases. Ms. Androski holds two BS degrees from the Massachusetts
Institute of Technology, JD and MBA degrees from The University of
Chicago, is a registered Patent Lawyer and a CFA charterholder
(under her former name of Lindsay Androski Kelly). Ms. Androski
also serves as a Trustee of the Massachusetts Institute of
Technology, and sits on the Visiting Committees for the Department
of Biology, the Department of Humanities, and Sponsored
Research.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is engaged in the science of
ribosome modulation, leveraging its innovative
TURBO-ZM™ chemistry technology platform in an effort to
develop novel Ribosome Modulating Agents (RMAs) and its library of
Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx’s lead
investigational product candidate, ELX-02, is a small molecule drug
candidate designed to restore production of full-length functional
proteins. The U.S. Food and Drug Administration (FDA) has granted
Fast Track designation for ELX-02 for the treatment of CF patients
with nonsense mutations. In addition, ELX-02 has also been granted
Orphan Drug Designation for the treatment of CF patients with
nonsense mutations by the FDA and orphan medicinal product
designation by the European Commission. ELX-02 is in clinical
development, focusing on cystic fibrosis (US Trial NCT04135495,
EU/IL Trial NCT04126473). Eloxx also has preclinical programs
focused on select rare diseases, including inherited diseases,
cancer caused by nonsense mutations, kidney diseases, including
autosomal dominant polycystic kidney disease, as well as rare
ocular genetic disorders.
For more information, please visit www.eloxxpharma.com.
Contact
InvestorsJohn
Woolfordjohn.woolford@westwicke.com443.213.0506
MediaLaureen Cassidylaureen@outcomescg.com
Source: Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Jul 2023 to Jul 2024